References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
The success of mRNA vaccines against COVID-19 has renewed interest in developing an mRNA vaccine for HIV. Several candidates are now in early clinical trials, though an effective HIV vaccine remains one of the biggest challenges in medicine. After more than 40 years of research, no HIV vaccine has yet proven effective enough for widespread use.
Here’s where the science stands and what the mRNA approach might change.
Why Is an HIV Vaccine So Difficult?
HIV has proven exceptionally difficult to vaccinate against for several reasons:
- Extreme genetic diversity: HIV mutates rapidly, producing countless variants. A vaccine that works against one strain may not protect against others.
- Immune evasion: HIV attacks the very immune cells (CD4 T-cells) that vaccines rely on to generate protection.
- Latent reservoir: HIV integrates its DNA into host cells, creating a hidden reservoir that the immune system can’t clear.
- No natural immunity model: Unlike most infections, virtually no one who contracts HIV clears the virus naturally, so there’s no “natural immune response” to mimic with a vaccine.
- Envelope protein shielding: HIV’s surface proteins are coated in sugars that hide them from antibodies.
How mRNA Vaccines Could Help
mRNA vaccines work by instructing cells to produce a specific protein that triggers an immune response. For HIV, researchers are exploring mRNA vaccines that could:
- Train the immune system to produce broadly neutralising antibodies (bnAbs) that work against multiple HIV strains
- Target conserved regions of HIV’s envelope protein that don’t mutate as readily
- Use sequential immunisation (multiple doses targeting different parts of HIV) to “guide” the immune system toward producing bnAbs
The key advantage of mRNA technology is speed and flexibility. Vaccine candidates can be designed, manufactured, and modified much faster than traditional protein-based vaccines.
Current Trials
As of 2025, several mRNA HIV vaccine candidates are in early-stage clinical trials:
- Moderna’s mRNA-1644: A germline-targeting vaccine designed to activate B-cells capable of producing bnAbs. Phase 1 trials showed the vaccine successfully activated the target B-cells in 97% of participants, a significant proof-of-concept.
- IAVI/Scripps G001: Another germline-targeting approach using protein nanoparticles (not mRNA), but informing mRNA vaccine design.
- Multiple academic programmes: Using mRNA to deliver HIV envelope trimers (the protein on HIV’s surface).
When Could an HIV Vaccine Be Available?
Even with promising early results, a licensed HIV vaccine is likely 10-15 years away at minimum. The current trials are Phase 1 (safety and immune response), and multiple rounds of larger trials would be needed before approval. Previous HIV vaccine candidates that showed promise in early trials have failed in larger studies.
In the meantime, PrEP remains the most effective biomedical HIV prevention tool. Read more: What is PrEP?
Read more: What is HIV? | Can HIV be cured?
Frequently Asked Questions
Can the COVID-19 vaccine protect against HIV?
No. The COVID-19 mRNA vaccines (Pfizer, Moderna) are specific to the SARS-CoV-2 virus. They have no effect on HIV. However, the mRNA technology platform developed for COVID-19 is being adapted for HIV vaccine research.
Has any HIV vaccine ever worked?
The RV144 trial in Thailand (2009) showed modest 31% efficacy using a different vaccine approach. No subsequent trial has matched or improved on this result. The mRNA approach represents a fundamentally different strategy.
Should I wait for a vaccine instead of taking PrEP?
No. An effective HIV vaccine is many years away. PrEP is available now, is 99% effective when taken consistently, and is free on the NHS. Don’t delay prevention while waiting for a future vaccine.
Related reading
- Can Condoms Protect Against HIV?
- Why Is an HIV Prevention Vaccine So Difficult to Develop?
- Do Condoms Prevent STIs?
- HIV Treatment as Prevention (TasP)
- How to Prevent HPV
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
